Cargando…

Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan

PURPOSE: Although expert guidelines for the treatment of schizophrenia recommend antipsychotic monotherapy, the use of antipsychotic polypharmacy is common. This study identified characteristics that differentiate patients with schizophrenia who are treated with olanzapine monotherapy versus polypha...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Wenyu, Ascher-Svanum, Haya, Flynn, Jennifer A, Tanji, Yuka, Takahashi, Michihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278200/
https://www.ncbi.nlm.nih.gov/pubmed/22347801
http://dx.doi.org/10.2147/CEOR.S25968
_version_ 1782223537534140416
author Ye, Wenyu
Ascher-Svanum, Haya
Flynn, Jennifer A
Tanji, Yuka
Takahashi, Michihiro
author_facet Ye, Wenyu
Ascher-Svanum, Haya
Flynn, Jennifer A
Tanji, Yuka
Takahashi, Michihiro
author_sort Ye, Wenyu
collection PubMed
description PURPOSE: Although expert guidelines for the treatment of schizophrenia recommend antipsychotic monotherapy, the use of antipsychotic polypharmacy is common. This study identified characteristics that differentiate patients with schizophrenia who are treated with olanzapine monotherapy versus polypharmacy in usual care in Japan. PATIENTS AND METHODS: In a large (N = 1850) prospective, observational study, Japanese patients with schizophrenia who initiated treatment with olanzapine were followed for 1 year. Consistent with past research, antipsychotic polypharmacy was defined as the concurrent use of olanzapine and another antipsychotic for at least 60 days. Switching was defined as discontinuing a prior antipsychotic therapy rather than augmenting the medication regimen. Predictors of antipsychotic monotherapy were based on information available at the time of olanzapine initiation. Baseline characteristics were compared using t-tests and χ(2) tests. Stepwise logistic regression was used to identify independent predictors of monotherapy. RESULTS: Patients treated with olanzapine monotherapy (43.2%) differed from those treated with antipsychotic polypharmacy (56.8%) on demographics, treatment history, baseline symptom levels, functional levels, and treatment-emergent adverse events. Stepwise logistic regression identified multiple variables that significantly predicted monotherapy: older age, shorter duration of schizophrenia, outpatient status, comorbid medical conditions, lower body mass index, no prior anticholinergic use, no prior mood stabilizer use, and switching from a previous antipsychotic (typical or atypical). CONCLUSION: Consistent with prior research in Japan, antipsychotic polypharmacy appears to be common in the treatment of schizophrenia. Patients treated with monotherapy could be differentiated from those treated with antipsychotic polypharmacy based on a specific set of demographic and baseline clinical characteristics.
format Online
Article
Text
id pubmed-3278200
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-32782002012-02-17 Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan Ye, Wenyu Ascher-Svanum, Haya Flynn, Jennifer A Tanji, Yuka Takahashi, Michihiro Clinicoecon Outcomes Res Original Research PURPOSE: Although expert guidelines for the treatment of schizophrenia recommend antipsychotic monotherapy, the use of antipsychotic polypharmacy is common. This study identified characteristics that differentiate patients with schizophrenia who are treated with olanzapine monotherapy versus polypharmacy in usual care in Japan. PATIENTS AND METHODS: In a large (N = 1850) prospective, observational study, Japanese patients with schizophrenia who initiated treatment with olanzapine were followed for 1 year. Consistent with past research, antipsychotic polypharmacy was defined as the concurrent use of olanzapine and another antipsychotic for at least 60 days. Switching was defined as discontinuing a prior antipsychotic therapy rather than augmenting the medication regimen. Predictors of antipsychotic monotherapy were based on information available at the time of olanzapine initiation. Baseline characteristics were compared using t-tests and χ(2) tests. Stepwise logistic regression was used to identify independent predictors of monotherapy. RESULTS: Patients treated with olanzapine monotherapy (43.2%) differed from those treated with antipsychotic polypharmacy (56.8%) on demographics, treatment history, baseline symptom levels, functional levels, and treatment-emergent adverse events. Stepwise logistic regression identified multiple variables that significantly predicted monotherapy: older age, shorter duration of schizophrenia, outpatient status, comorbid medical conditions, lower body mass index, no prior anticholinergic use, no prior mood stabilizer use, and switching from a previous antipsychotic (typical or atypical). CONCLUSION: Consistent with prior research in Japan, antipsychotic polypharmacy appears to be common in the treatment of schizophrenia. Patients treated with monotherapy could be differentiated from those treated with antipsychotic polypharmacy based on a specific set of demographic and baseline clinical characteristics. Dove Medical Press 2012-01-13 /pmc/articles/PMC3278200/ /pubmed/22347801 http://dx.doi.org/10.2147/CEOR.S25968 Text en © 2012 Ye et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Ye, Wenyu
Ascher-Svanum, Haya
Flynn, Jennifer A
Tanji, Yuka
Takahashi, Michihiro
Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan
title Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan
title_full Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan
title_fullStr Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan
title_full_unstemmed Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan
title_short Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan
title_sort predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in japan
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278200/
https://www.ncbi.nlm.nih.gov/pubmed/22347801
http://dx.doi.org/10.2147/CEOR.S25968
work_keys_str_mv AT yewenyu predictorsofantipsychoticmonotherapywitholanzapineduringa1yearnaturalisticstudyofschizophreniapatientsinjapan
AT aschersvanumhaya predictorsofantipsychoticmonotherapywitholanzapineduringa1yearnaturalisticstudyofschizophreniapatientsinjapan
AT flynnjennifera predictorsofantipsychoticmonotherapywitholanzapineduringa1yearnaturalisticstudyofschizophreniapatientsinjapan
AT tanjiyuka predictorsofantipsychoticmonotherapywitholanzapineduringa1yearnaturalisticstudyofschizophreniapatientsinjapan
AT takahashimichihiro predictorsofantipsychoticmonotherapywitholanzapineduringa1yearnaturalisticstudyofschizophreniapatientsinjapan